Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023551272> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2023551272 endingPage "8" @default.
- W2023551272 startingPage "1" @default.
- W2023551272 abstract "Aminobisphosphonates, synthetic analogues of endogenous pyrophosphate, have been widely used for the treatment of osteoporosis and bone metastases characterized by excessive osteoclastic bone resorption. Such aminobisphosphonates can be recognized by human γδ T cells having inherent Vγ2Vδ2 T cell receptors (TCRs) circulating in the blood. Here we show that risedronate, one of the most potent aminobisphosphonates, together with 10 U/ml IL-2, strongly expanded both CD8αα-positive and double negative Vγ2Vδ2 T cells among freshly isolated peripheral blood mononuclear cells (PBMCs) from healthy individuals in vitro. The optimal concentration of risedronate was 5 μM and the expanded Vγ2Vδ2 T cells secreted a good amount of IFN-γ as well as small amount of TNF-α but not IL-4. Complete abrogation of IFN-γ production was observed in Vδ2-depleted PBMCs when stimulated with 5 μM of risedronate for 7 days. However, oral administration with risedronate had no effect on the absolute number of Vγ2Vδ2 T cells in PBMCs and risedronate medication for 8 weeks did not prime those γδ T cells for proliferation by in vitro restimulation. Nonetheless, we did observe transient enhancement of IFN-γ production in the supernatant 48 h after the risedronate stimulation among 3 out of 6 patients on either two or four weeks after the medication. These data suggest that orally administered risedronate can commit Vγ2Vδ2-positive γδ T cells to IFN-γ-secreting effectors in vivo." @default.
- W2023551272 created "2016-06-24" @default.
- W2023551272 creator A5005258111 @default.
- W2023551272 creator A5017032625 @default.
- W2023551272 creator A5025067812 @default.
- W2023551272 creator A5040132448 @default.
- W2023551272 creator A5055394881 @default.
- W2023551272 creator A5089289647 @default.
- W2023551272 date "2004-01-01" @default.
- W2023551272 modified "2023-10-17" @default.
- W2023551272 title "Orally administrated risedronate can commit V.GAMMA.2V.DELTA.2 T cells to IFN-.GAMMA. secreting effectors in patients with osteoporosis" @default.
- W2023551272 cites W1484185978 @default.
- W2023551272 cites W1497645868 @default.
- W2023551272 cites W1530002712 @default.
- W2023551272 cites W1948558382 @default.
- W2023551272 cites W1987608235 @default.
- W2023551272 cites W1993232754 @default.
- W2023551272 cites W2003797329 @default.
- W2023551272 cites W2017842295 @default.
- W2023551272 cites W2026391181 @default.
- W2023551272 cites W2026821111 @default.
- W2023551272 cites W2038731517 @default.
- W2023551272 cites W2041971745 @default.
- W2023551272 cites W2112660458 @default.
- W2023551272 cites W2133449490 @default.
- W2023551272 cites W2141672711 @default.
- W2023551272 cites W2145434557 @default.
- W2023551272 cites W2164120157 @default.
- W2023551272 cites W2170263258 @default.
- W2023551272 cites W2198237500 @default.
- W2023551272 cites W2325302070 @default.
- W2023551272 cites W2991587873 @default.
- W2023551272 cites W60551495 @default.
- W2023551272 doi "https://doi.org/10.2220/biomedres.25.1" @default.
- W2023551272 hasPublicationYear "2004" @default.
- W2023551272 type Work @default.
- W2023551272 sameAs 2023551272 @default.
- W2023551272 citedByCount "3" @default.
- W2023551272 crossrefType "journal-article" @default.
- W2023551272 hasAuthorship W2023551272A5005258111 @default.
- W2023551272 hasAuthorship W2023551272A5017032625 @default.
- W2023551272 hasAuthorship W2023551272A5025067812 @default.
- W2023551272 hasAuthorship W2023551272A5040132448 @default.
- W2023551272 hasAuthorship W2023551272A5055394881 @default.
- W2023551272 hasAuthorship W2023551272A5089289647 @default.
- W2023551272 hasBestOaLocation W20235512721 @default.
- W2023551272 hasConcept C126322002 @default.
- W2023551272 hasConcept C153180980 @default.
- W2023551272 hasConcept C203014093 @default.
- W2023551272 hasConcept C2776541429 @default.
- W2023551272 hasConcept C2778690821 @default.
- W2023551272 hasConcept C2780841837 @default.
- W2023551272 hasConcept C41008148 @default.
- W2023551272 hasConcept C502942594 @default.
- W2023551272 hasConcept C51785407 @default.
- W2023551272 hasConcept C71924100 @default.
- W2023551272 hasConcept C77088390 @default.
- W2023551272 hasConcept C98274493 @default.
- W2023551272 hasConceptScore W2023551272C126322002 @default.
- W2023551272 hasConceptScore W2023551272C153180980 @default.
- W2023551272 hasConceptScore W2023551272C203014093 @default.
- W2023551272 hasConceptScore W2023551272C2776541429 @default.
- W2023551272 hasConceptScore W2023551272C2778690821 @default.
- W2023551272 hasConceptScore W2023551272C2780841837 @default.
- W2023551272 hasConceptScore W2023551272C41008148 @default.
- W2023551272 hasConceptScore W2023551272C502942594 @default.
- W2023551272 hasConceptScore W2023551272C51785407 @default.
- W2023551272 hasConceptScore W2023551272C71924100 @default.
- W2023551272 hasConceptScore W2023551272C77088390 @default.
- W2023551272 hasConceptScore W2023551272C98274493 @default.
- W2023551272 hasIssue "1" @default.
- W2023551272 hasLocation W20235512721 @default.
- W2023551272 hasOpenAccess W2023551272 @default.
- W2023551272 hasPrimaryLocation W20235512721 @default.
- W2023551272 hasRelatedWork W2036276565 @default.
- W2023551272 hasRelatedWork W2126903562 @default.
- W2023551272 hasRelatedWork W2344495349 @default.
- W2023551272 hasRelatedWork W2354350842 @default.
- W2023551272 hasRelatedWork W2358157500 @default.
- W2023551272 hasRelatedWork W2387223170 @default.
- W2023551272 hasRelatedWork W2404992560 @default.
- W2023551272 hasRelatedWork W2414229545 @default.
- W2023551272 hasRelatedWork W4248933460 @default.
- W2023551272 hasRelatedWork W4252538451 @default.
- W2023551272 hasVolume "25" @default.
- W2023551272 isParatext "false" @default.
- W2023551272 isRetracted "false" @default.
- W2023551272 magId "2023551272" @default.
- W2023551272 workType "article" @default.